Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Lumos Pharma ( (LUMO) ).
Lumos Pharma, Inc. has announced the completion of its merger with DPV Parent, Inc. which resulted in the delisting of its shares from Nasdaq. The merger agreement involved a tender offer by DPV MergerSub, Inc., a wholly owned subsidiary of DPV Parent, to purchase all outstanding shares of Lumos Pharma’s common stock for a cash amount plus contingent value rights. Consequently, all equity incentive plans and controlled equity agreements were terminated, and former Lumos shareholders and option holders will receive cash and contingent value rights as per the agreement terms. These changes signal a significant restructuring and a shift in market positioning for Lumos Pharma, impacting its stakeholders by transforming the company’s operational structure and shareholding framework.
More about Lumos Pharma
YTD Price Performance: 36.48%
Average Trading Volume: 93,039
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $37.54M
For an in-depth examination of LUMO stock, go to TipRanks’ Stock Analysis page.
